Evidence of involvement of human CYP3A in the 3-hydroxylation of quinine

British Journal of Clinical Pharmacology

Volumn 43, Issue 3, 1997, Pages 245-252

  Zhang, H ^a   Coville, P F ^a   Walker, R J ^a   Miners, J O ^b   Birkett, D J ^b   Wanwimolruk, S ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

CYP3A; drug metabolism; human liver microsomes; quinine

Indexed keywords

3 HYDROXYQUININE; 4 NITROPHENOL; CAFFEINE; DRUG METABOLITE; MIDAZOLAM; OMEPRAZOLE; PHENACETIN; QUININE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 0031043842     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00556.x     Document Type: Article

References (42)

1. WHO technical report. Series 805. Geneva: Switzerland, 1990.
2. White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol. 1992; 34: 1-10.
3. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986; 30: 287-295.
4. Tamai G, Yoshida H, Takashina T, et al. Isolation of new quinidine metabolites and simultaneous determination of quinidine and its metabolites in blood and urine by direct injection HPLC analysis. Chromatographia 1985; 20: 671-676.
5. Liddle C, Graham GG, Christopher RK, Bhuwapathanapun S, Duffield AM. Identification of new urinary metabolites in man of quinine using methane chemical ionization gas chromatography-mass spectrometry. Xenobiotica 1981; 11: 81-87.
6. Brodie BB, Baer JE, Craig LC. Metabolic products of the cinchona alkaloids in human urine. J Biol Chem 1951; 188: 567-581.
7. Wanwimolruk S, Wong SM, Coville PF, Walker RJ. In vitro hepatic microsomal metabolism of quinine: identification of P450 enzymes responsible for quinine metabolism. Can J Physiol Pharmacol 1994; 72 (Suppl 1): 294.
8. Wanwimolruk S, Wong SM, Zhang H, Coville PF, Walker RJ. Metabolism of quinine in man: 1. Identification of a major metabolite, and effect of smoking and rifampicin pretreatment. J Pharm Pharmacol 1995; 47: 957-963.
9. Wanwimolruk S, Wong SM, Coville PF, Viriyayudhakorn S, Thitiarchakul S. Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol 1993; 36: 610-614.
10. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and characterisation of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P-450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
11. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P-450IIIA induction. Br J Clin Pharmacol 1989; 28: 373-387.
12. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363-372.
13. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH. Metabolism of 2-actylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P450. Cancer Res 1990; 50: 3367-3376.
14. Robson RA, Matthews AP, Miners JO, et al. Characterisation of theophylline metabolism by human liver microsomes. Br J Clin Pharmacol 1987; 24: 293-300.
15. Wanwimolruk S, Wong SM, Zhang H, Coville PF. Simultaneous determination of quinine and a major metabolite 3-hydroxyquinine in biological fluids by HPLC without extraction. J Liq Chromatogr 1996; 19: 293-305.
16. Dixon M, Webb EC. Enzyme kinetics. In Enzymes, Third Edition, London: Longmans, 1979: 47-206.
17. Tassaneeyakul W, Mohamed Z, Birkett DJ, et al. Caffeine as a probe for human cytochrome P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992; 2: 173-183.
18. Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450IA2 by furafylline. Chem Res Toxicol 1993; 6: 649-656.
19. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533-538.
20. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by -S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37: 423-420.
21. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-130.
22. Tassaneeyakul W, Birkett DJ, McManus ME, et al. Caffeine metabolism by human cytochrome P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994; 47: 1767-1776.
23. Birkett DJ, Mackenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 1993; 14: 292-294.
24. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipme, erythromycin, cimetidine, and nizatidine. Pharmaceutical Res 1994; 11: 921-924.
25. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401-407.
26. Tassaneeyakul W, Veronese ME, Birkett DJ, Miners JO. High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P450 2E1 activity, in human liver microsomes. J Chromatogr 1993; 616: 73-78.
27. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. BrJ Clin Pharmacol 1993; 36: 521-530.
28. Kronbach T, Mathy D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
29. Beedham C, Al-Tayib Y, Smith JA. Role of guinea pig and rabbit hepatic aldehyde oxidase in oxidative in vitro metabolism of cinchona antimalarials. Drug Metab Dispos 1992; 20: 889-895.
30. Murray M, Gordon FR. Selectivity in the inhibition of mammalian cytochrome P450 by chemical agents. Pharmacol Rev 1990; 42: 85-100.
31. Okey AB. Enzyme induction in the cytochrome P450 enzymes. Pharmacol Ther 1990; 45: 241-298.
32. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB J 1992; 6: 745-748.
33. Guengerich FP. Enzymatic oxidation of xenobiotic chemicals. CRC Crit Rev Biochem Mol Biol 1990; 25: 97-153.
34. Gorski JC, Hall SD, Jones DR, Vandenbranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP 3A) subfamily. Biochem Pharmacol 1994; 47: 1643-1653.
35. Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J Pharmacol Exp Ther 1994; 268: 1160-1165.
36. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993; 43: 120-126.
37. Wrighton SA, Stevens JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Tox 1992; 22: 1-21.
38. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.
39. Smith DA. Species difference in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 1991; 23: 355-373.
40. Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S. Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol 1995; 40: 87-91.
41. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993; 25: 453-484.
42. Ching MS, Blake CL, Ghabrial H, Smallwood RA. Quinine and quinidine are protent inhibitors of CYP1A1 cloned in yeast. (Abstract). Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, December 4-7, 1994, Auckland, New Zealand. 1994; 1: 22.